An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation

Athanasios Paschos, Andreas Den Hartigh, Mark A. Smith, Vidya L. Atluri, Durga Sivanesan, Renee M Tsolis, Christian Baron

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

As bacterial pathogens develop resistance against most currently used antibiotics, novel alternatives for treatment of microbial infectious diseases are urgently needed. Targeting bacterial virulence functions in order to disarm pathogens represents a promising alternative to classical antibiotic therapy. Type IV secretion systems, which are multiprotein complexes in the cell envelope that translocate effectors into host cells, are critical bacterial virulence factors in many pathogens and excellent targets for such " antivirulence" drugs. The VirB8 protein from the mammalian pathogen Brucella was chosen as a specific target, since it is an essential type IV secretion system component, it participates in multiple protein-protein interactions, and it is essential for the assembly of this translocation machinery. The bacterial two-hybrid system was adapted to assay VirB8 interactions, and a high-throughput screen identified specific small-molecule inhibitors. VirB8 interaction inhibitors also reduced the levels of VirB8 and of other VirB proteins, and many of them inhibited virB gene transcription in Brucella abortus 2308, suggesting that targeting of the secretion system has complex regulatory effects in vivo. One compound strongly inhibited the intracellular proliferation of B. abortus 2308 in a J774 macrophage infection model. The results presented here show that in vivo screens with the bacterial two-hybrid assay are suited to the identification of inhibitors of Brucella type IV secretion system function.

Original languageEnglish (US)
Pages (from-to)1033-1043
Number of pages11
JournalInfection and Immunity
Volume79
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Brucella abortus
Brucella
Proteins
Anti-Bacterial Agents
Multiprotein Complexes
Two-Hybrid System Techniques
Virulence Factors
Communicable Diseases
Virulence
Macrophages
Type IV Secretion Systems
Infection
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Parasitology
  • Infectious Diseases

Cite this

An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation. / Paschos, Athanasios; Den Hartigh, Andreas; Smith, Mark A.; Atluri, Vidya L.; Sivanesan, Durga; Tsolis, Renee M; Baron, Christian.

In: Infection and Immunity, Vol. 79, No. 3, 03.2011, p. 1033-1043.

Research output: Contribution to journalArticle

Paschos, Athanasios ; Den Hartigh, Andreas ; Smith, Mark A. ; Atluri, Vidya L. ; Sivanesan, Durga ; Tsolis, Renee M ; Baron, Christian. / An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation. In: Infection and Immunity. 2011 ; Vol. 79, No. 3. pp. 1033-1043.
@article{ffbcdb6a0ded47669a1e8fe2bd27c9f2,
title = "An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation",
abstract = "As bacterial pathogens develop resistance against most currently used antibiotics, novel alternatives for treatment of microbial infectious diseases are urgently needed. Targeting bacterial virulence functions in order to disarm pathogens represents a promising alternative to classical antibiotic therapy. Type IV secretion systems, which are multiprotein complexes in the cell envelope that translocate effectors into host cells, are critical bacterial virulence factors in many pathogens and excellent targets for such {"} antivirulence{"} drugs. The VirB8 protein from the mammalian pathogen Brucella was chosen as a specific target, since it is an essential type IV secretion system component, it participates in multiple protein-protein interactions, and it is essential for the assembly of this translocation machinery. The bacterial two-hybrid system was adapted to assay VirB8 interactions, and a high-throughput screen identified specific small-molecule inhibitors. VirB8 interaction inhibitors also reduced the levels of VirB8 and of other VirB proteins, and many of them inhibited virB gene transcription in Brucella abortus 2308, suggesting that targeting of the secretion system has complex regulatory effects in vivo. One compound strongly inhibited the intracellular proliferation of B. abortus 2308 in a J774 macrophage infection model. The results presented here show that in vivo screens with the bacterial two-hybrid assay are suited to the identification of inhibitors of Brucella type IV secretion system function.",
author = "Athanasios Paschos and {Den Hartigh}, Andreas and Smith, {Mark A.} and Atluri, {Vidya L.} and Durga Sivanesan and Tsolis, {Renee M} and Christian Baron",
year = "2011",
month = "3",
doi = "10.1128/IAI.00993-10",
language = "English (US)",
volume = "79",
pages = "1033--1043",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - An in vivo high-throughput screening approach targeting the type IV secretion system component VirB8 identified inhibitors of Brucella abortus 2308 proliferation

AU - Paschos, Athanasios

AU - Den Hartigh, Andreas

AU - Smith, Mark A.

AU - Atluri, Vidya L.

AU - Sivanesan, Durga

AU - Tsolis, Renee M

AU - Baron, Christian

PY - 2011/3

Y1 - 2011/3

N2 - As bacterial pathogens develop resistance against most currently used antibiotics, novel alternatives for treatment of microbial infectious diseases are urgently needed. Targeting bacterial virulence functions in order to disarm pathogens represents a promising alternative to classical antibiotic therapy. Type IV secretion systems, which are multiprotein complexes in the cell envelope that translocate effectors into host cells, are critical bacterial virulence factors in many pathogens and excellent targets for such " antivirulence" drugs. The VirB8 protein from the mammalian pathogen Brucella was chosen as a specific target, since it is an essential type IV secretion system component, it participates in multiple protein-protein interactions, and it is essential for the assembly of this translocation machinery. The bacterial two-hybrid system was adapted to assay VirB8 interactions, and a high-throughput screen identified specific small-molecule inhibitors. VirB8 interaction inhibitors also reduced the levels of VirB8 and of other VirB proteins, and many of them inhibited virB gene transcription in Brucella abortus 2308, suggesting that targeting of the secretion system has complex regulatory effects in vivo. One compound strongly inhibited the intracellular proliferation of B. abortus 2308 in a J774 macrophage infection model. The results presented here show that in vivo screens with the bacterial two-hybrid assay are suited to the identification of inhibitors of Brucella type IV secretion system function.

AB - As bacterial pathogens develop resistance against most currently used antibiotics, novel alternatives for treatment of microbial infectious diseases are urgently needed. Targeting bacterial virulence functions in order to disarm pathogens represents a promising alternative to classical antibiotic therapy. Type IV secretion systems, which are multiprotein complexes in the cell envelope that translocate effectors into host cells, are critical bacterial virulence factors in many pathogens and excellent targets for such " antivirulence" drugs. The VirB8 protein from the mammalian pathogen Brucella was chosen as a specific target, since it is an essential type IV secretion system component, it participates in multiple protein-protein interactions, and it is essential for the assembly of this translocation machinery. The bacterial two-hybrid system was adapted to assay VirB8 interactions, and a high-throughput screen identified specific small-molecule inhibitors. VirB8 interaction inhibitors also reduced the levels of VirB8 and of other VirB proteins, and many of them inhibited virB gene transcription in Brucella abortus 2308, suggesting that targeting of the secretion system has complex regulatory effects in vivo. One compound strongly inhibited the intracellular proliferation of B. abortus 2308 in a J774 macrophage infection model. The results presented here show that in vivo screens with the bacterial two-hybrid assay are suited to the identification of inhibitors of Brucella type IV secretion system function.

UR - http://www.scopus.com/inward/record.url?scp=79952287929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952287929&partnerID=8YFLogxK

U2 - 10.1128/IAI.00993-10

DO - 10.1128/IAI.00993-10

M3 - Article

C2 - 21173315

AN - SCOPUS:79952287929

VL - 79

SP - 1033

EP - 1043

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 3

ER -